These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 30531133)

  • 1. [Safety and management of adverse events of ixazomib/lenalidomide/dexamethasone therapy in Japanese patients with relapsed/refractory multiple myeloma].
    Iida S; Izumi T; Aotsuka N; Komeno T; Ishida T; Sunami K; Handa H; Berg D; Kase Y; Soeda J
    Rinsho Ketsueki; 2018; 59(11):2399-2407. PubMed ID: 30531133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.
    Kumar S; Moreau P; Hari P; Mateos MV; Ludwig H; Shustik C; Masszi T; Spencer A; Hájek R; Romeril K; Avivi I; Liberati AM; Minnema MC; Einsele H; Lonial S; Berg D; Lin J; Gupta N; Esseltine DL; Richardson PG
    Br J Haematol; 2017 Aug; 178(4):571-582. PubMed ID: 28485007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.
    Hou J; Jin J; Xu Y; Wu D; Ke X; Zhou D; Lu J; Du X; Chen X; Li J; Liu J; Gupta N; Hanley MJ; Li H; Hua Z; Wang B; Zhang X; Wang H; van de Velde H; Richardson PG; Moreau P
    J Hematol Oncol; 2017 Jul; 10(1):137. PubMed ID: 28683766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
    Moreau P; Masszi T; Grzasko N; Bahlis NJ; Hansson M; Pour L; Sandhu I; Ganly P; Baker BW; Jackson SR; Stoppa AM; Simpson DR; Gimsing P; Palumbo A; Garderet L; Cavo M; Kumar S; Touzeau C; Buadi FK; Laubach JP; Berg DT; Lin J; Di Bacco A; Hui AM; van de Velde H; Richardson PG;
    N Engl J Med; 2016 Apr; 374(17):1621-34. PubMed ID: 27119237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
    Richardson PG; Kumar SK; Masszi T; Grzasko N; Bahlis NJ; Hansson M; Pour L; Sandhu I; Ganly P; Baker BW; Jackson SR; Stoppa AM; Gimsing P; Garderet L; Touzeau C; Buadi FK; Laubach JP; Cavo M; Darif M; Labotka R; Berg D; Moreau P
    J Clin Oncol; 2021 Aug; 39(22):2430-2442. PubMed ID: 34111952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone
    Mateos MV; Masszi T; Grzasko N; Hansson M; Sandhu I; Pour L; Viterbo L; Jackson SR; Stoppa AM; Gimsing P; Hamadani M; Borsaru G; Berg D; Lin J; Di Bacco A; van de Velde H; Richardson PG; Moreau P
    Haematologica; 2017 Oct; 102(10):1767-1775. PubMed ID: 28751562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma.
    Hájek R; Minařík J; Straub J; Pour L; Jungova A; Berdeja JG; Boccadoro M; Brozova L; Spencer A; van Rhee F; Vela-Ojeda J; Thompson MA; Abonour R; Chari A; Cook G; Costello CL; Davies FE; Hungria VT; Lee HC; Leleu X; Puig N; Rifkin RM; Terpos E; Usmani SZ; Weisel KC; Zonder JA; Bařinová M; Kuhn M; Šilar J; Čápková L; Galvez K; Lu J; Elliott J; Stull DM; Ren K; Maisnar V
    Future Oncol; 2021 Jul; 17(19):2499-2512. PubMed ID: 33769076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma.
    Suzuki K; Handa H; Chou T; Ishizawa K; Takubo T; Kase Y
    Int J Hematol; 2017 Apr; 105(4):445-452. PubMed ID: 28000099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed/refractory multiple myeloma.
    Hari P; Lin HM; Zhu Y; Berg D; Richardson PG; Moreau P
    J Med Econ; 2018 Aug; 21(8):793-798. PubMed ID: 29741409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.
    Facon T; Venner CP; Bahlis NJ; Offner F; White DJ; Karlin L; Benboubker L; Rigaudeau S; Rodon P; Voog E; Yoon SS; Suzuki K; Shibayama H; Zhang X; Twumasi-Ankrah P; Yung G; Rifkin RM; Moreau P; Lonial S; Kumar SK; Richardson PG; Rajkumar SV
    Blood; 2021 Jul; 137(26):3616-3628. PubMed ID: 33763699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib-lenalidomide-dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study.
    Lee HC; Ramasamy K; Macro M; Davies FE; Abonour R; van Rhee F; Hungria VTM; Puig N; Ren K; Silar J; Enwemadu V; Cherepanov D; Leleu X
    Eur J Haematol; 2024 Aug; 113(2):190-200. PubMed ID: 38654611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study.
    Li J; Bao L; Xia Z; Wang S; Zhou X; Ding K; Zhang W; Yang W; Li B; Fu C; Chen B; Hua L; Wang L; Luo J; Yang Y; Xu T; Wang W; Huang Y; Wu G; Liu P
    Ann Hematol; 2020 Nov; 99(11):2589-2598. PubMed ID: 32892275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma.
    Terpos E; Ramasamy K; Maouche N; Minarik J; Ntanasis-Stathopoulos I; Katodritou E; Jenner MW; Plonkova H; Gavriatopoulou M; Vallance GD; Pika T; Kotsopoulou M; Kothari J; Jelinek T; Kastritis E; Aitchison R; Dimopoulos MA; Zomas A; Hajek R
    Ann Hematol; 2020 May; 99(5):1049-1061. PubMed ID: 32236735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial.
    Dimopoulos MA; Schjesvold F; Doronin V; Vinogradova O; Quach H; Leleu X; Montes YG; Ramasamy K; Pompa A; Levin MD; Lee C; Mellqvist UH; Fenk R; Demarquette H; Sati H; Vorog A; Labotka R; Du J; Darif M; Kumar S
    Blood Cancer J; 2022 Jan; 12(1):9. PubMed ID: 35075109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Effectiveness of Ixazomib Dose-escalating Strategy in Ixazomib-Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma.
    Ohashi Y; Yatabe M; Niijima D; Tani K; Ogawa C; Yachi Y; Kagoo T; Boku S; Ueno H; Yano T; Higai K; Yokoyama A
    In Vivo; 2020; 34(5):2821-2828. PubMed ID: 32871820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma.
    Richardson PG; Hofmeister CC; Rosenbaum CA; Htut M; Vesole DH; Berdeja JG; Liedtke M; Chari A; Smith SD; Lebovic D; Raje N; Byrne C; Liao E; Gupta N; Bacco AD; Estevam J; Berg D; Baz R
    Br J Haematol; 2018 Jul; 182(2):231-244. PubMed ID: 29938772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202).
    Voorhees PM; Suman VJ; Tuchman SA; Laubach JP; Hassoun H; Efebera YA; Mulkey F; Bova-Solem M; Santo K; Carlisle D; McCarthy PL; Richardson PG
    Am J Hematol; 2021 Dec; 96(12):1595-1603. PubMed ID: 34559902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.
    Avet-Loiseau H; Bahlis NJ; Chng WJ; Masszi T; Viterbo L; Pour L; Ganly P; Palumbo A; Cavo M; Langer C; Pluta A; Nagler A; Kumar S; Ben-Yehuda D; Rajkumar SV; San-Miguel J; Berg D; Lin J; van de Velde H; Esseltine DL; di Bacco A; Moreau P; Richardson PG
    Blood; 2017 Dec; 130(24):2610-2618. PubMed ID: 29054911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A real-world retrospective-prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience.
    Furlan A; Cea M; Pavan L; Galli M; Clissa C; Mangiacavalli S; Cafro AM; Girlanda S; Patriarca F; Minotto C; Bertoldero G; Barilà G; Pascarella A; Lico A; Paolini R; Rabassi N; Pescosta N; Porrazzo M; De Sabbata G; Pompa A; Bega G; Cavallin S; Guidotti F; Marcatti M; Rupolo M; Belotti A; Gherlinzoni F; Zambello R
    Cancer Med; 2024 Apr; 13(7):e7071. PubMed ID: 38558233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ixazomib, lenalidomide, and dexamethasone combination in "real-world" clinical practice in patients with relapsed/refractory multiple myeloma.
    Sokol J; Guman T; Chudej J; Hlebaskova M; Stecova N; Valekova L; Kucerikova M; Stasko J
    Ann Hematol; 2022 Jan; 101(1):81-89. PubMed ID: 34550463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.